The Elenitoba-Johnson and Megan Lim Lab focuses on the role of genomic and proteomic alterations in the pathogenesis of lymphomas.
Research
The research interests of the Elenitoba-Johnson-Lim lab encompass genomic and functional proteomic approaches to discover novel mechanisms of lymphoma pathogenesis; development of conditional murine models for investigating the role of oncogenes and tumor suppressor genes in lymphocyte development and lymphomas genesis and translational research utilizing innovative genomic and mass spectrometry-based approaches focused on identification of novel genomic and proteomic targets for diagnostic and therapeutic applications.
Current Projects:
- Role of FBXO45 E3 ubiquitin ligase and its substrates in lymphocyte differentiation and lymphomagenesis
- Mass spectrometry-based functional proteomic approaches to identify novel oncogenic mediators of lymphomas
- Genomic approaches for early disease detection and prognostication for cutaneous T cell lymphoma and splenic lymphoma
- Role of tyrosine kinase gene fusions such as NPM1::ALK and NPM1::TYK2 in T cell differentiation and lymphomagenesis
- Epigenetic mechanisms of tumor evasion in lymphoma
- Epiproteomic signatures of lymphoma
Bio
Distinctions:
- James Ewing Alumni Chair, Department of Pathology, Memorial Sloan Kettering Cancer Center (2022)
- President, Association for Molecular Pathology (2017-2018)
- Inaugural Peter C. Nowell, MD, Chair, Founding Director, Center for Personalized Diagnostics, University of Pennsylvania (2015)
- Outstanding Investigator Award, American Society of Investigative Pathology (former Warner-Lambert/AMGEN, 2012)
- Elected Member, American Society for Clinical Investigation (2011)
- Ramzi Cotran Young Investigator US Canadian Academy of Pathology Award (2006)